The company will receive GMP compliance certificate which will further help to accelerate the business growth across the globe
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management
In the US, the compassionate use approvals are provided by FDA in the form of individual patient-specific expanded-access IND
According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
A 40 minute daily Yoga routine, incorporating select asanas and pranayama, along with standard lifestyle interventions, can reduce the risk of developing diabetes by approximately 40%
Harnessing advanced data analysis for early detection, prevention and better outcomes
Zefylti will be available as 30 MU/0.5 mL and 48 MU/0.5 mL and is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells
This product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.
Subscribe To Our Newsletter & Stay Updated
